The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

BACKGROUND: A multi-biomarker disease activity (MBDA) score has been validated as an objective measure of disease activity in rheumatoid arthritis (RA) and shown to track response to treatment with several disease-modifying anti-rheumatic drugs (DMARDs). The objective of this study was to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Roodenrijs, Nadia M. T., de Hair, Maria J. H., Wheater, Gill, Elshahaly, Mohsen, Tekstra, Janneke, Teng, Y. K. Onno, Lafeber, Floris P. J. G., Hwang, Ching Chang, Liu, Xinyu, Sasso, Eric H., van Laar, Jacob M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245625/
https://www.ncbi.nlm.nih.gov/pubmed/30458871
http://dx.doi.org/10.1186/s13075-018-1750-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245625/
https://www.ncbi.nlm.nih.gov/pubmed/30458871
http://dx.doi.org/10.1186/s13075-018-1750-5

Ejemplares similares